Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas (NCT00624416), a non-randomized phase 1, phase 2 study. The primary outcome is The Average Percent Volume Reduction in the Lipoma..

2. Clinical Question

At the level of the registry record, the central question is whether the listed injection combination was associated with change in lipoma volume over the stated follow-up period. The brief summary also describes interest in fat released by fat cells and in whether injections might shrink lipomas. Those statements describe the study's aims; they are not results.

The distinction between an intended comparison and the registered design matters. A comparison with isoproterenol alone would require information about participants receiving that comparator and a suitable analysis. The registry instead classifies the study as a non-randomized, single-group study and lists only the combination intervention. It therefore does not establish a like-for-like control comparison. Whether a comparator was used in practice is not reported in the registry record.

3. Trial Design

NCT00624416, titled “Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas,” is listed as a completed pilot study sponsored by Pennington Biomedical Research Center. The registry classifies it as Phase 1 and Phase 2, non-randomized, unmasked, and single-group. Enrollment was 10 participants. The recorded study start was 2007-10, and primary completion was 2009-03.

The intervention entry names prednisolone and isoproterenol together. The arm description calls the intervention a beta-adrenergic agonist and corticosteroid. Although the brief summary mentions comparing the combination with isoproterenol alone, the registered design and arm information do not show a separate comparator group. The study should therefore not be read as a randomized or controlled comparison on the basis of this record. Whether the conduct differed from the registered description is not reported in the registry record.

The primary outcome is average percent volume reduction in the lipoma, with a timeframe of baseline and 4 weeks. Two secondary outcomes are listed: the number of lipomas that increased in volume and the number of subjects who elected to have the lipoma removed. The registry lists 3 outcome measures overall, but does not report their numerical results.

The registry identifies no statistical analyses. It does not report the protocol details needed to assess how the intervention was administered, how lipoma volume was measured, how participants were selected, or how the outcome data were handled. The rationale for the enrollment target and any planned interim analyses are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as The Average Percent Volume Reduction in the Lipoma., measured over Baseline and 4 weeks.

The primary endpoint is titled “The Average Percent Volume Reduction in the Lipoma.” It is described as a mean, with full range as the dispersion measure, and is assessed from baseline to 4 weeks. This endpoint is intended to represent change in the size of the lipoma over the stated observation period. Volume is a continuous measurement, so describing the group average can give a concise account of the typical measured change; the full range can also convey how widely individual observations varied.

In general, a percentage change expresses a change relative to a baseline measurement, which can make changes easier to interpret when starting volumes differ. That interpretation depends on consistent measurement and a clearly defined calculation. The registry does not provide the volume-measurement procedure, the calculation details, or the observed baseline and follow-up values. It therefore is not possible to assess the endpoint's measurement precision or independently interpret the size of any change.

The outcome title and timeframe are not an outcome result. No average percent volume reduction, range, uncertainty interval, or statistical test is reported in the registry record. The endpoint description alone cannot establish whether volume changed, how consistent any change was across participants, or how precisely a group-level estimate was determined.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation begins by identifying the question, design, endpoint, and analysis population. For NCT00624416, the registered design is non-randomized and single-group, and the primary endpoint is average percent volume reduction between baseline and 4 weeks. The registry lists 10 enrolled participants but does not report an analysis population, endpoint results, or statistical analyses. The distinction between the stated study aim and the registered design is important: the brief summary describes a combination-versus-isoproterenol-alone comparison, while the registered arm information lists only the combination.

What does a single-group design allow?

In general, a single-group study can describe the outcomes observed among participants who receive the listed intervention. A change from baseline can be summarized within that group if the measurements and analysis are available. Such a change does not, by itself, separate an intervention-associated change from other explanations, including the natural course of the condition, measurement variation, or other changes over time. A concurrent comparison group can help address some alternative explanations, but a separate comparator is not reported in the registry record.

Non-randomized allocation also means assignment is not described as random. In general, random assignment aims to reduce systematic differences between groups, while non-randomized comparisons can be affected by how participants enter or receive treatments. Here, the record identifies a single-group model, so it does not describe an allocation process between treatment groups. The registry does not report whether a comparator was used outside the registered information.

What does the endpoint summary mean?

The primary outcome is a mean, a summary of the measured values in a group. The listed dispersion is the full range, which describes the lowest and highest observed values. General statistical interpretation benefits from both a central summary and information about spread: participants may have similar changes or markedly different changes even if their average is the same. The record provides no numerical mean or range, so neither the central result nor the observed spread can be interpreted.

A confidence interval, in general, communicates uncertainty around an estimate under the assumptions of the analysis. It is not a guarantee that a particular range contains the true value. Its width depends on factors including variability, sample size, and the analysis method. No confidence interval is reported for the primary endpoint. A p-value, in general, evaluates how compatible data are with a specified null model under defined assumptions; it does not measure clinical importance or the probability that a hypothesis is true. No p-value or hypothesis test is reported.

How should planning calculations be distinguished from results?

General sample-size calculations use assumptions about a target effect, variability, significance level, power, allocation, and analysis method. The planning assumptions recorded for illustrations use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the target effect is expressed as a stated fraction of an observed effect. Those assumptions describe an illustration, not a documented design justification for this single-group pilot. The registry does not report the trial's own sample-size rationale.

Planning sample sizes are not observed power. Observed power is not a substitute for reporting an effect estimate and its uncertainty. In this case, an observed effect is not reported, and no calculated planning values are stated in the registry entries. No conclusion about the adequacy of the enrollment target can be drawn from the planning assumptions alone.

Why does dispersion matter?

General methods for continuous outcomes often rely on assumptions about how observations vary. If variability is greater than an analysis assumes, standard errors and uncertainty intervals may be poorly calibrated. Over-dispersion refers generally to variability exceeding what a model expects; it matters because an overly restrictive model can make estimates appear more precise than warranted. The registry does not describe a model, provide outcome data, or report any assessment of dispersion. It is therefore not possible to say whether over-dispersion occurred or affected an analysis.

The full range can be sensitive to extreme observations and does not show the shape of the distribution. A range alone cannot establish whether most participants had changes near the average or whether a small number of observations strongly influenced it. Individual measurements, distribution summaries, and the analysis method are not reported in the registry record.

What can be inferred from the analysis record?

The registry lists 3 outcome measures and 0 analyses. The presence of an outcome definition indicates what was planned or recorded as an outcome, not that a result was posted. The absence of analysis results means that estimates, uncertainty, model assumptions, and handling of missing observations cannot be evaluated. Details about transformations, covariate adjustment, or sensitivity analyses are not reported in the registry record.

These general principles help explain what information would be needed for a statistical assessment, but they do not fill gaps in the trial record. The available information identifies the design, enrollment, intervention listing, endpoint, and outcome timeframe. It does not provide the data or analysis needed to quantify the endpoint or judge its precision.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary outcome and 2 secondary outcomes, and records 3 outcome measures overall. When a study evaluates multiple outcomes or performs multiple tests, the chance of at least one apparently unusual result can increase. General approaches to multiplicity include identifying a primary analysis in advance, adjusting inference across tests, or treating secondary findings as exploratory. The registry does not report a multiplicity strategy, statistical analysis plan, or results for these outcomes. No claim about adjustment or unadjusted inference can therefore be made.

Missing-data handling is also not reported in the registry record. The enrollment count is 10, but the number of participants with an observed primary outcome, the number with complete follow-up, and reasons for any missing measurements are not reported. It is not possible to determine whether all enrolled participants contributed to the outcome summary or whether missingness could have affected interpretation.

An analysis population can refer to the participants included under a defined analysis rule. General examples include analyzing participants according to original assignment or restricting analysis to those with particular measurements, but the appropriate approach depends on the design and question. No analysis population or inclusion rule is reported for this study. Because the registered design is single-group, information about assignment-based analysis cannot be inferred from the record.

The registry records 0 analyses. It does not report how the primary or secondary outcomes were analyzed, whether any observations were excluded, or whether sensitivity analyses were conducted. These gaps limit reproducibility and make it impossible to assess the influence of missing observations or multiple outcome testing on the reported evidence.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry's adverse-event information lists 10 participants at risk for serious events and 0 affected. For other events, it also lists 10 at risk and 0 affected. The death count is not reported in the registry record. No top serious-event terms are listed.

These entries should be read as the counts recorded in the registry, not as proof that no events occurred outside the reporting captured there. The record does not provide event definitions, observation details, severity categories beyond the serious-versus-other grouping, or further information about how events were collected. It also does not provide a narrative explaining the null death entry.

In general, safety counts describe reported events in the population and period covered by the record. They do not, by themselves, establish the absence of risk or support comparisons with another treatment. Here, a separate comparator is not reported in the registered design, and the study enrolled 10 participants. The figures should therefore be interpreted narrowly as the posted counts, without extrapolating beyond the registry record.

12. What the Result Does, and Does Not, Mean

The registry establishes that NCT00624416 was recorded as a completed pilot study sponsored by Pennington Biomedical Research Center. It identifies a non-randomized, unmasked, single-group design, enrollment of 10, a combination intervention, and a primary outcome concerning average percent lipoma volume reduction from baseline to 4 weeks. It also lists secondary outcomes concerning increases in lipoma volume and elective removal.

Those design details do not establish what happened to lipoma volume. The primary result and secondary outcome results are not reported in the registry record. No numerical estimate, range, confidence interval, or statistical test is available for interpretation. The posted information therefore cannot show the size or direction of any observed change, how participants' outcomes varied, or how precise an estimate might be.

The brief summary's proposed comparison with isoproterenol alone should not be mistaken for evidence from a controlled comparison. The registered model is single-group, and a separate comparator arm is not reported. Without a concurrent comparator and appropriate analysis, a before-and-after observation would not by itself distinguish change associated with the intervention from other influences. Whether any unregistered comparator was used is not reported in the registry record.

In general, “completed” describes study status, not the strength or direction of findings. Likewise, “pilot” describes the study's designation and does not reveal the sample-size justification or intended inferential threshold. Those details are not reported. The record's safety counts are limited to the posted entries and do not establish broader safety conclusions.

The appropriate interpretation is consequently bounded: the registry documents a small pilot study and its registered outcome framework, but it does not supply the results required to judge the observed endpoint or its uncertainty. Neither a positive nor a negative treatment conclusion follows from the absence of posted outcome estimates.

13. Why This Trial Matters Statistically

This study is statistically instructive because its stated aim and registered design do not align cleanly. The brief summary describes comparing a medication combination with isoproterenol alone, whereas the registered model is single-group and the listed arm describes the combination. Recognizing that distinction prevents an intended comparison from being interpreted as a documented controlled analysis.

The primary endpoint also illustrates the difference between defining an outcome and reporting its result. The registry specifies average percent volume reduction and a baseline-to-4-week timeframe, but does not report the observed mean or full range. Without those values, readers cannot assess magnitude, variation, or precision. Outcome labels alone are not evidence of an outcome finding.

The record is also a reminder that a small enrollment does not, by itself, determine whether a study is useful or whether a result is precise. That assessment requires the observed data, the analysis, and the design rationale. The sample-size justification and analysis plan are not reported in the registry record. Planning calculations, if considered, must be kept separate from observed results and from the trial's documented design.

Finally, missing analysis details are not merely technical omissions. Reporting the analysis population, missing-data handling, and approach to multiple outcomes helps readers understand how conclusions were reached and how robust they may be. Those details, along with numerical outcome results, are not reported. The record therefore offers a useful case in separating registered intentions and design metadata from evidence that can support statistical interpretation.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry gives limited information about how this pilot was conducted. It records the design as non-randomized, unmasked, and single-group, but does not report detailed eligibility criteria, participant characteristics, or the intervention dose and schedule. These omissions restrict assessment of who the findings would represent and how consistently the intervention may have been administered.

The primary outcome is named and timed, but the measurement procedure and calculation details are not reported in the registry record. No baseline or follow-up values, average percent reduction, full range, or inferential results are posted. The absence of outcome results prevents assessment of the endpoint itself, regardless of the study's completion status.

The mismatch between the brief summary's proposed comparison and the registered single-group model is a further limitation for interpretation. A separate comparator is not listed, so the record does not support a like-for-like treatment comparison. The reason for the mismatch is not reported.

Details about missing measurements, analysis populations, multiplicity, model choice, and sensitivity analyses are not reported. The record also does not give a sample-size justification or interim-analysis plan. The small enrollment of 10 is a recorded design feature, but without outcome variability and analysis results, its consequences for precision cannot be quantified. These limitations are specific to what the registry record documents and should not be treated as proof that unreported procedures or analyses did not occur.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas — NCT00624416.
• Registry record last updated 2015-12-21; status last verified 2015-12.
• Results first posted 2012-06-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00624416 is a completed pilot study sponsored by Pennington Biomedical Research Center, with enrollment of 10. The registry identifies Phase 1 and Phase 2, non-randomized allocation, no masking, and a single-group model. Its recorded start was 2007-10, with primary completion in 2009-03.

The listed intervention is prednisolone with isoproterenol. The primary outcome is average percent volume reduction in the lipoma from baseline to 4 weeks. Two secondary outcomes concern lipomas increasing in volume and subjects electing removal. Although the brief summary describes a comparison with isoproterenol alone, a separate comparator is not reported in the registered design.

The registry does not report numerical outcome results or statistical analyses. Serious and other event counts each list 0 affected among 10 at risk; the death count is not reported in the registry record. The record documents the study framework but does not provide enough outcome information to assess efficacy or estimate statistical precision.